Treatment
Cytarabine clinical trials
We’re tracking 156 recruiting studies that include Cytarabine, each written for real people, not researchers, below.
Recruiting studies
- NCT06361329RecruitingPhase 3
Comparing new drug combo to standard chemo for ETP-ALL
This trial compares a new combination of drugs (venetoclax plus chemotherapy) to standard chemotherapy for people newly diagnosed with a rare type of T-cell leukemia called ETP-ALL. The goal is to see if the new regimen works better.
Hangzhou, ZhejiangAges 14–75 - NCT05603884RecruitingPhase 2
New treatment plan for older adults with newly diagnosed AML
This trial studies a two-part chemotherapy plan for older adults newly diagnosed with acute myeloid leukemia (AML) who can’t take the usual standard induction treatment. It aims to improve how well treatment works while taking into account age and other health conditions.
Xiamen, FujianAges 60 years+ - NCT07387926RecruitingPhase 1/Phase 2
Testing asciminib for children and young adults with a type of leukemia
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Sydney, New South WalesAges 1–30 - NCT07244367Recruiting
Venetoclax maintenance for AML fit patients
This trial tests whether taking venetoclax can help keep your leukemia from coming back after you reach complete remission. It is for patients who are not able to get a bone marrow transplant right away.
SohagAges 18–60 - NCT07227584RecruitingPhase 2
ALL treatment for adolescents and young adults
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
Boston, MassachusettsAges 18–51 - NCT07223814RecruitingPhase 3
Testing a new drug with standard chemo for AML
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
Los Angeles, CaliforniaAges 18 years+ - NCT03643276RecruitingPhase 3
Study of treatment plans for children with leukemia
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
SydneyAges Up to 17 years - NCT07199296RecruitingPhase 2
Study of orelabrutinib and rituximab with optional stem cell transplant for mantle cell lymphoma
This trial is testing a combination of two targeted drugs, orelabrutinib and rituximab, as a first treatment for mantle cell lymphoma (MCL). Some patients may also get a stem cell transplant. The goal is to see how well this approach works.
ShanghaiAges 14 years+ - NCT05959720Recruiting
Teen-to-adult ALL study using a pediatric chemotherapy plan
This trial tests a treatment plan for newly diagnosed acute lymphoblastic leukemia (ALL) in people ages 16 to 50. It aims to see how well a “pediatric-style” regimen works, but it only fits certain genetic and health profiles.
São Paulo, São PauloAges 16–50 - NCT07131059Recruiting
Study for MRD-positive AML in remission
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT07132684RecruitingPhase 3
Comparing two chemotherapy plans for older AML patients
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
TianjinAges 55–75 - NCT07108530RecruitingPhase 2
Chemotherapy and transplant for adult acute myeloid leukemia
This trial tests a combination of chemotherapy and stem cell transplant for adults with acute myeloid leukemia (AML) that is not a specific subtype called APL. It aims to see if this approach is more effective than standard treatments.
Taiyuan, ShanxiAges 14–65 - NCT07078591RecruitingPhase 2
Venetoclax with mini transplant for new AML
This trial tests combining the medicine Venetoclax with a mini stem-cell transplant from a partially matched relative for people with newly diagnosed acute myeloid leukemia (AML). It may help control the leukemia while reducing transplant side effects.
BeijingAges 18 years+ - NCT07059975RecruitingEarly Phase 1
Improved monitoring and treatment for pediatric acute myeloid leukemia
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
Houston, TexasAges 1 month–30 years - NCT07060001RecruitingPhase 2
Comparing two leukemia treatments using a blood test
This trial compares two standard treatments for newly diagnosed acute myeloid leukemia (AML) to see if a simple blood test can help predict how well each treatment works. The goal is to find the best treatment approach for each person.
Houston, TexasAges 18 years+ - NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+ - NCT07032727RecruitingPhase 2
Olutasidenib plus targeted therapy for relapsed IDH1-mutated myeloid cancers
This trial tests a combination of olutasidenib with other targeted drugs for people with certain blood cancers that have returned or not responded to treatment. It focuses on patients who have both an IDH1 mutation and a second activating mutation in specific signaling genes.
Miami, FloridaAges 18 years+ - NCT07022678RecruitingPhase 3
Xylitol dental wipes to reduce infection risk in childhood leukemia
This trial tests whether using xylitol dental wipes can lower the risk of bloodstream infections in children with acute myeloid leukemia (AML) who are receiving chemotherapy. If you or your child have AML and will have at least two cycles of chemo that include cytarabine, this study may help reduce infection risk.
Birmingham, AlabamaAges 1–25 - NCT07007312RecruitingPhase 3
Ziftomenib plus standard chemo for certain AML patients
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
Gilbert, ArizonaAges 18 years+ - NCT07012447RecruitingPhase 2
Venetoclax with azacytidine for newly diagnosed T-cell leukemia
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
Suzhou, JiangsuAges 14 years+ - NCT05253495RecruitingPhase 2
Targeted immunotherapy added to chemotherapy and radiation for lymphoma
This Phase 2 trial tests whether adding targeted immunotherapy to standard chemotherapy and radiation can improve outcomes in children with certain types of lymphoma. It may help the immune system work better against cancer.
Birmingham, AlabamaAges 3–39 - NCT06942039RecruitingEarly Phase 1
Study of two drugs for young children with aggressive brain tumors
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
Calgary, AlbertaAges Up to 6 years - NCT06930352RecruitingPhase 2
Ziftomenib for newly diagnosed AML with NPM1 or KMT2A changes
This trial tests an oral drug called ziftomenib for people with a type of acute myeloid leukemia (AML) that has certain genetic changes (NPM1 mutation or KMT2A rearrangement) and who are not able to receive standard chemotherapy. The goal is to see if ziftomenib can help control the leukemia.
Columbus, OhioAges 18 years+ - NCT06928662RecruitingPhase 1/Phase 2
Chemo, radiation, and donor stem cell transplant for high-risk blood cancers
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Seattle, WashingtonAges 18 years+
Common questions
- Are there clinical trials studying Cytarabine?
- Yes. Clin2 currently lists 156 recruiting studies that include Cytarabine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cytarabine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cytarabine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cytarabine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.